Smith & Nephew plc (LON: SN)
London
· Delayed Price · Currency is GBP · Price in GBp | Market Cap | 8.96B |
| Revenue (ttm) | 4.46B |
| Net Income (ttm) | 241.34M |
| Shares Out | 871.99M |
| EPS (ttm) | 0.28 |
| PE Ratio | 37.22 |
| Forward PE | 13.42 |
| Dividend | 0.30 (2.97%) |
| Ex-Dividend Date | Oct 3, 2024 |
| Volume | 356,892 |
| Average Volume | 2,419,596 |
| Open | 1,026.50 |
| Previous Close | 1,028.00 |
| Day's Range | 1,023.00 - 1,029.00 |
| 52-Week Range | 911.00 - 1,245.26 |
| Beta | 0.69 |
| RSI | 64.96 |
| Earnings Date | Feb 25, 2025 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other... [Read more]
Financial Performance
In 2023, Smith & Nephew's revenue was $5.55 billion, an increase of 6.40% compared to the previous year's $5.22 billion. Earnings were $263.00 million, an increase of 17.94%.
Financial numbers in USD Financial StatementsNews
Smith & Nephew (SNN) Stock Surges Amid Strong Financial Performance
Smith & Nephew (SNN) Stock Surges Amid Strong Financial Performance
Smith & Nephew PLC (SNN) Receives Favorable Ratings for Advanced Wound Care Solutions
Smith & Nephew PLC (SNN) Receives Favorable Ratings for Advanced Wound Care Solutions
Smith+Nephew's ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable' Evidence Bar™ ratings from ECRI for pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence A...
Topical Scar Treatment Market to Grow from $1.71 Billion in 2024 to $5.91 Billion by 2035 - Dominated by Smith & Nephew, Molnlycke Health Care, Alliance Pharma, HRA Pharma, and Rejuvaskin
Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally
Smith & Nephew chief Deepak Nath in 'last chance saloon'
They will pressure Nath to resign in the New Year unless he proves that the FTSE 100 firm has made operational improvements.
Smith & Nephew PLC (SNN) Expands CORI Surgical System with FDA-Cleared Hip Arthroplasty Planning
Smith & Nephew PLC (SNN) Expands CORI Surgical System with FDA-Cleared Hip Arthroplasty Planning
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announc...
Smith & Nephew PLC (SNN) Receives FDA Clearance for AETOS Stemless Shoulder System
Smith & Nephew PLC (SNN) Receives FDA Clearance for AETOS Stemless Shoulder System
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total...
Big investors call for break-up of Smith & Nephew, FT reports
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
Big investors call for break-up of Smith & Nephew
Medical devices company should consider spinning off orthopaedics unit, say three top-20 shareholders
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew investors may push for breakup - Mail on Sunday
Shareholders of Smith & Nephew (SNN) may push for a breakup if CEO Deepak Nath fails to improve performance, particularly in the orthopaedics division.
Smith & Nephew falls as Berenberg downgrades to Hold
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ETCompany ParticipantsDeepak Nath - CEO & DirectorJohn...
MARKET REPORT: Smith & Nephew rocked by slowdown in China
Smith & Nephew anticipates full-year sales growth of 4.5%, not 5% to 6%. Sales in the third-quarter were up 4% - or 5.9% excluding China - to £1.1bn.
Smith & Nephew stock slumps after China-tied profit warning
Three Quick Facts: Smith & Nephew, Shell and Spectris
Shell profits beat expectations after higher gas sales, Smith & Nephew profit margins trimmed and headwinds set to drag at Spectris
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its su...
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design ...
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-ma...
Smith & Nephew goes ex dividend tomorrow
Smith & Nephew plc goes ex dividend tomorrow
This stock is 'boring' but has 'fantastic' risk-reward: Scharf
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors.
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Desig...